Art. -Nr.: HY-B1907A

Rifamycin

(Synonyms: Rifamycin SV)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.06%
CAS. Nr.: 6998-60-3
Formel: C₃₇H₄₇NO₁₂
Molecular Weight:697.77

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Rifamycin Chemical Structure

CAS. Nr.: 6998-60-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Cancer cell lines	GI₅₀	10 μM Compound: Rifamycin SV	Growth inhibition of human Colon cancer cells Growth inhibition of human Colon cancer cells	[PMID: 25205189]
Cancer cell lines	GI₅₀	10 μM Compound: Rifamycin SV	Growth inhibition of human Prostate cancer cells Growth inhibition of human Prostate cancer cells	[PMID: 25205189]
Cancer cell lines	GI₅₀	15.9 μM Compound: Rifamycin SV	Growth inhibition of human Renal cancer cells Growth inhibition of human Renal cancer cells	[PMID: 25205189]
Cancer cell lines	GI₅₀	16.6 μM Compound: Rifamycin SV	Growth inhibition of human Breast cancer cells Growth inhibition of human Breast cancer cells	[PMID: 25205189]
Cancer cell lines	GI₅₀	18.6 μM Compound: Rifamycin SV	Growth inhibition of human Ovarian cancer cells Growth inhibition of human Ovarian cancer cells	[PMID: 25205189]
Cancer cell lines	GI₅₀	21.4 μM Compound: Rifamycin SV	Growth inhibition of human CNS cancer cells Growth inhibition of human CNS cancer cells	[PMID: 25205189]
HEK293	IC₅₀	0.23 μM Compound: Rifamycin SVd	TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells	[PMID: 15616150]
Leukemia cell	GI₅₀	3.2 μM Compound: Rifamycin SV	Growth inhibition of human Leukemia cells Growth inhibition of human Leukemia cells	[PMID: 25205189]
Melanoma cell	GI₅₀	15.5 μM Compound: Rifamycin SV	Growth inhibition of human Melanoma cells Growth inhibition of human Melanoma cells	[PMID: 25205189]
NSCLC	GI₅₀	14.5 μM Compound: Rifamycin SV	Growth inhibition of human NSCLC cells Growth inhibition of human NSCLC cells	[PMID: 25205189]
Sf21	IC₅₀	3.1 μM Compound: Rifamycin SV	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	6.3 μM Compound: Rifamycin SV	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Vero	CC₅₀	62.46 μg/mL Compound: RFM	Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin assay Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin assay	[PMID: 23474387]

In Vitro

Rifamycin (10 μM; 30 s) mainly inhibits -independent Taurocholate (HY-N0545) uptake in short-term cultured rat hepatocytes^[2].
Rifamycin (10-100 μM; 15 min) effectively inhibits Oatp2-mediated Taurocholate uptake in Xenopus oocytes expressing Na⁺/Ntcp^[2].
Rifamycin (1-100 μM; 24 h) inhibits the synthesis of cytokines and chemokines from lipopolysaccharide-activated monocytes and macrophages^[3].
Rifamycin (0.16 μg/ml; 2 weeks of culture) inhibits the growth of M. tuberculosis and its drug-resistant mutants in TB broth containing 10% serum albumin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rifamycin (5 mg/day; s.c.; 3 days a week) is effective in mice infected with M. tuberculosis, significantly reducing the number of viable bacteria in the body^[4].
Rifamycin (12.5-25 mg/kg; peritoneal lavage) can improve the survival rate of rats with experimental intraperitoneal infection and significantly reduce the number of intraperitoneal bacteria and adhesion formation^[6].
Rifamycin (5-40 mg/kg; esophageal gavage; once a day, 5 days a week; 4 weeks) shortens oral treatment duration in a mouse model of Mycobacterium ulcerans disease^[8].
Rifamycin (0.1 mL; intraaural administration; twice daily; 10 days) does not cause hearing loss in adult or weanling rats^[9].
Rifamycin (1 mg i.v. bolus followed by 4 mg i.v. infusion; 70 min) interferes with three major steps of Bile acid metabolism in rats with intravenous Sodium cholate (HY-N0324A) infusion, resulting in a significant decrease in bile acid uptake and excretion^[10].
Rifamycin (10-160 mg/kg; s.c.; single dose) is approximately 11 times less effective than Metronidazole (HY-B0318) in a mouse Bacteroides fragilis thigh infection model^[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (weight 200-250 g), cecal ligation puncture (CLP)-induced intra-abdominal infection model^[6]
Dosage:

25 mg/kg, 12.5 mg/kg
Administration:

Peritoneal lavage
Result:

Improved survival from 50% in the control group to 91.7% in the 25 mg/kg group and 100% in the 12.5 mg/kg group.
Significantly reduced adhesion formation.
Showed a greater reduction in bacterial counts in peritoneal fluid (25 mg/kg).

Chemical Information

CAS. Nr. 6998-60-3
Appearance Solid
Molecular Weight 697.77
Formel C₃₇H₄₇NO₁₂
Color Light yellow to brown
SMILES

C[C@H]1/C=C/C=C(C)\C(NC2=CC(O)=C3C(C(O)=C(C)C4=C3C([C@](O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@H]1O)(C)O4)=O)=C2O)=O
Synonyms

Rifamycin SV
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [Abstract]

2026 Mar;13(16):e13310. PMID: 41589654
Proc Natl Acad Sci U S A

Structure-guided approach to modulate small molecule binding to a promiscuous ligand-activated protein. [Abstract]

2023 Mar 7;120(10):e2217804120. PMID: 36848571

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (143.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4331 mL

7.1657 mL

14.3314 mL

5 mM

0.2866 mL

1.4331 mL

2.8663 mL

10 mM

0.1433 mL

0.7166 mL

1.4331 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Floss HG, et al. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. [Content Brief]

[2]. Fattinger K, et al. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology. 2000 Jul;32(1):82-6. [Content Brief]

[3]. Rosette C, et al. Anti-inflammatory and immunomodulatory activities of rifamycin SV. Int J Antimicrob Agents. 2013 Aug;42(2):182-6. [Content Brief]

[4]. Tsukamura M, et al. Antituberculous Action of Rifamycin SV* In Vitro and In Vivo Studies. The Journal of Antibiotics, Series A, 1962, 15(5): 216-224.

[5]. Saito K, et al. Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations. Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. [Content Brief]

[6]. Jallouli M, et al. Rifamycin lavage in the treatment of experimental intra-abdominal infection. J Surg Res. 2009 Aug;155(2):191-4. [Content Brief]

[7]. Zhang M, et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. [Content Brief]

[8]. Omansen TF, et al. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01478-18. [Content Brief]

[9]. Özbay C, et al. Ototoxic effect of topical rifamycin SV applied in the middle ear of rats. The Turkish Journal of Ear Nose and Throat, 2017, 27(1): 31-38.

[10]. Okolicsanyi L, et al. Influence of rifamycin SV on bile acid metabolism in rats. Naunyn Schmiedebergs Arch Pharmacol. 1980 Aug;313(2):171-4. [Content Brief]

[11]. Dijkmans B A C, et al. Efficacy of rifamycin SV and vancomycin against Bacteroides fragilis in vitro and in experimentally infected mice. Current Microbiology, 1985, 12: 53-58.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4331 mL	7.1657 mL	14.3314 mL	35.8284 mL
	5 mM	0.2866 mL	1.4331 mL	2.8663 mL	7.1657 mL
	10 mM	0.1433 mL	0.7166 mL	1.4331 mL	3.5828 mL
	15 mM	0.0955 mL	0.4777 mL	0.9554 mL	2.3886 mL
	20 mM	0.0717 mL	0.3583 mL	0.7166 mL	1.7914 mL
	25 mM	0.0573 mL	0.2866 mL	0.5733 mL	1.4331 mL
	30 mM	0.0478 mL	0.2389 mL	0.4777 mL	1.1943 mL
	40 mM	0.0358 mL	0.1791 mL	0.3583 mL	0.8957 mL
	50 mM	0.0287 mL	0.1433 mL	0.2866 mL	0.7166 mL
	60 mM	0.0239 mL	0.1194 mL	0.2389 mL	0.5971 mL
	80 mM	0.0179 mL	0.0896 mL	0.1791 mL	0.4479 mL
	100 mM	0.0143 mL	0.0717 mL	0.1433 mL	0.3583 mL

Keywords

Rifamycin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Rifamycin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Macrocyclic Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Pediatric Drug Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Rifamycin

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Rifamycin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Macrocyclic Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Pediatric Drug Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Rifamycin

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Rifamycin Related Classifications

HY-B1907A Related Classifications